

This translational study was the first to demonstrate that the adiponectin receptor agonist ALY688 mediated cardioprotective effects in a mouse model of heart failure with reduced ejection fraction (HFrEF). Mechanistic changes included alterations in fibrosis, hypertrophy, inflammation and metabolic dysfunction. Our study establishes ALY688 as a promising therapeutic approach for treating HFrEF in a clinical setting.